Last edition
News about
Pin Therapeutics Administers First Dose of PIN-5018 in Adenoid Cystic Carcinoma Patient
Pin Therapeutics, a clinical-stage biotechnology company focused on targeted protein degradation, has begun dosing in a Phase 1 clinical trial evaluating its CK1α-selective degrader, PIN-5018. The first patient enrolled in the study has adenoid cystic carcinoma (ACC), a rare malignancy with limited treatment options.
AGC Biologics has partnered with AAVantgarde Bio to manufacture its dual-vector AAV gene therapies targeting inherited retinal disorders. Leveraging the BravoAAV platform, the collaboration aims to advance complex treatments designed to restore vision in patients with genetic blindness.
Alkem Launches De Simone Formulation Probiotic DSS in India
Alkem Laboratories has introduced DSS, the original De Simone formulation probiotic blend, to the Indian market for restoring gut microbiota balance and managing a wide range of gastrointestinal conditions.
Abbott India Gets Central Government Nod for New Managing Director
Abbott India has announced that the Central Government has approved the appointment of Kartik Rajendran as the company’s Managing Director for a five-year term, effective June 14, 2025, to June 13, 2030.
Harbour BioMed, AstraZeneca Advance Next-Gen Oncology Biotherapeutics Collaboration
Harbour BioMed has announced an update on the advancement of its global strategic collaboration with AstraZeneca to discover and develop next-generation biotherapeutics in oncology, including antibody-drug conjugates (ADCs) and T cell engagers.
US FDA Approves PADCEV plus Keytruda for Certain Patients with Bladder Cancer
PADCEV plus Keytruda is the first and only approved perioperative treatment regimen that can improve survival over current standard of care (surgery alone) in cisplatin-ineligible patients with Muscle-Invasive Bladder Cancer (MIBC).
Shimadzu Medical Systems USA to Unveil MobileDaRt Evolution MX9 Version
Shimadzu Medical Systems USA is set to unveil the MobileDaRt Evolution MX9 Version at the upcoming RSNA Technical Exhibits in Chicago, showcasing enhanced mobility, improved operator visibility, and instant on-board image verification for faster clinical decisions.
Fischer Medical Ventures Subsidiary Powers Philippines' First Locally-Funded MRI Facility in Bulacan
The Province of Bulacan has inaugurated the Philippines’ first locally funded Magnetic Resonance Imaging (MRI) facility—developed by Time Medical International Ventures (India), a wholly owned subsidiary of Fischer Medical Ventures.
Aurobindo Pharma's China Facility Running at Loss, Eyes Break-Even by Q4
The company’s CFO, S. Subramanian, indicated that while the plant is operating below margin, it is ramping up production and is on track to contribute positively to the company’s EBITDA in the near future.
AstraZeneca Plans USD 2 Billion Manufacturing Investment in Maryland
AstraZeneca will invest USD 2 billion to expand its biologics manufacturing in Maryland, boosting production of cancer, rare disease, and chronic therapies while supporting around 2,600 jobs.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy